Resumo

ESTRADA-MARTINEZ, Luis Enrique et al. Atypical dose of bevacizumab in a patient with Osler-Weber Rendu syndrome. Med. interna Méx. [online]. 2018, vol.34, n.4, pp.649-657. ISSN 0186-4866.  https://doi.org/10.24245/mim.v34i4.1884.

Osler-Weber-Rendu syndrome is an autosomical dominant condition. Although epistaxis is the most frequent symptom, many other visceral implications have to be considered while the workup takes place. While Anti-VEGF are the cornerstone of the treatment, there is no consensus regarding the specific dose to be administered. We communicate de case of a patient with Osler-Weber-Rendu syndrome attended at our Hospital in which we prescribed an atypical dose of bevacizumab with good outcome.

Palavras-chave : Osler-Weber-Rendu Syndrome; Bevacizumab; Telangiectasis; Epistaxis.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )